Navigation Links
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:11/1/2008

com" target="_new">http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's clinical development plans and the potential for boceprevir. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A, "Risk Factors" in the company's third quarter 2008 10-Q.

Endnotes

1. Kwo P, Lawitz E, McCone J, et al. Boceprevir Plus Peginterferon alfa-2b/Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients: Interim Results from the HCV SPRINT-1 Study. 59th American Association for the Study of Liver Diseases (AASLD) Annual Meeting; Oct. 31-Nov. 2, 2008, San Francisco, CA, USA; Poster No. LB16.

2. SVR, the protocol specified primary efficacy endpoint, is defined as achievement of undetectable HCV-RNA at 24 weeks after the end of treatment. Per protocol, if a patient does not have a 24-week post-treatment assessment, the patient's 12-week post-treatment assessment will be utilized.

3. SVR 12 is defined as undetectable HCV-RNA in plasma at 12 weeks after the end of treatment. The protocol specified primary effic
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
5. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
6. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   Assurex Health, a personalized medicine ... providers for behavioral health and chronic pain conditions, ... in equity financing from new and existing investors, ... and Chief Executive Officer. The financing ... Assurex Health,s GeneSight ®  products.  GeneSight,s ...
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin Pharmaceutical ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today announced that the Company achieved the ... Manufacturing Practice (GMP) certificate of TPI,s Qionglai Facility ... (CFDA). The public notice period is a significant ...
(Date:12/24/2014)... 23, 2014  Medical Science Liaisons play a large ... between the medical device industry and key stakeholders, the ... coming years as the device industry relies on them ... research by benchmarking firm, Best Practices, LLC, one area ... edge is by harnessing new technology to enable education. ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Role of Medical Science Liaisons Evolving in Medical Device Sector 2
(Date:12/25/2014)... When head lice hits a home or school, parents and ... of it while keeping it from taking over the house ... solution right in their neighborhood: Lice Troopers . Expanding ... spectrum head lice screening and treatment services to families and ... Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , The ...
(Date:12/25/2014)... (HealthDay News) -- The risk of burns from fires ... need to be extra cautious, an expert says. ... significant increase in patients coming in with burns," said ... Volunteer Firefighters Burn Center of Stony Brook University Hospital ... of joy, but if not careful, could quickly turn ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as part of ... applications on the iOS, Android, and Windows markets. Andrew Tropeano, ... app review and shared with viewers how this is an ... saying goes, “A picture says a thousand words.” It’s true. ... single image, because each picture holds a unique and special ...
(Date:12/25/2014)... Santa Rosa, CA (PRWEB) December 25, 2014 ... emergency department visits and 2 million hospital admissions across ... Control and Prevention ). The CDC’s National Hospital ... emergency departments through a survey conducted in 2010. They ... emergency department visits that resulted in a primary diagnosis ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... smoke a little or a lot, study finds , TUESDAY, March ... at much higher risk of developing lung cancer from exposure to ... with it, a new study finds. , Researchers also found that ... they light up a lot or a little. , "If you ...
... ... women important and potentially life-changing information about pregnancy health, fertility health, and women,s health. ... Edmonton, Alberta ... its new website. The new Pregnancy Health website gives Canadian women important and potentially ...
... ... Tabs and Summarized Demographic Reporting increases value of Intellimed,s Reporting Tool. , ... Phoenix, Ariz. (PRWEB) March 9, ... announces new enhancements to it’s popular medical reporting software system Intellimed Intelligent Client (IM-IC)., ...
... ... 2010 ECRM Cough & Cold and Allergy Conference. It is a nasal-sinus irrigation system ... and the associated risk of sinus re-infection, growing concerns in the medical community. The ... ...
... ... ... ... ...
... ... ... , , , , ... ...
Cached Medicine News:Health News:Genetic Variant Raises Lung Cancer Risk 2Health News:Pregnancy Health Centre Launches Website to Help Women 2Health News:Intellimed's Popular Data Reporting Software IM-IC (Intelligent Client) Receives Latest Update 2Health News:TechWorld Medicals NasalCare Nasal Cleanse Kit Named “Best New Product” at ECRM Cough & Cold and Allergy Conference 2Health News:TechWorld Medicals NasalCare Nasal Cleanse Kit Named “Best New Product” at ECRM Cough & Cold and Allergy Conference 3Health News:MedInformatix EPM and EMR Standardizes Care, Raises Efficiency for Affiliates of Non-Profit Physicians Network 2Health News:MedInformatix EPM and EMR Standardizes Care, Raises Efficiency for Affiliates of Non-Profit Physicians Network 3Health News:MedInformatix EPM and EMR Standardizes Care, Raises Efficiency for Affiliates of Non-Profit Physicians Network 4Health News:MedInformatix EPM and EMR Standardizes Care, Raises Efficiency for Affiliates of Non-Profit Physicians Network 5Health News:MedInformatix EPM and EMR Standardizes Care, Raises Efficiency for Affiliates of Non-Profit Physicians Network 6Health News:MedInformatix EPM and EMR Standardizes Care, Raises Efficiency for Affiliates of Non-Profit Physicians Network 7Health News:K-State Study Finds Abundance of Food Stores, Not Lack of Them, Puts Low-Income Women In Small Cities at Higher Risk of Obesity 2Health News:K-State Study Finds Abundance of Food Stores, Not Lack of Them, Puts Low-Income Women In Small Cities at Higher Risk of Obesity 3Health News:K-State Study Finds Abundance of Food Stores, Not Lack of Them, Puts Low-Income Women In Small Cities at Higher Risk of Obesity 4Health News:K-State Study Finds Abundance of Food Stores, Not Lack of Them, Puts Low-Income Women In Small Cities at Higher Risk of Obesity 5Health News:K-State Study Finds Abundance of Food Stores, Not Lack of Them, Puts Low-Income Women In Small Cities at Higher Risk of Obesity 6
... CellTracks® Analyzer II is ... used to enumerate fluorescently ... immunomagnetically selected and aligned. ... the CellTracks® Analyzer II, ...
... These unique Acid Fast ... sputum smear with appropriate background ... containing a positive and negative ... Kinyoun (Cat. No. 353), Ziehl-Neelsen ...
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Medicine Products: